Neuren Pharmaceuticals (ASX:NEU) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 25, 2026)


ASX:NEU Neuren Pharmaceuticals Ltd ASX:NEU
54 GF Score
Price A$12.76
GF Value A$6.08
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Neuren Pharmaceuticals Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Neuren Pharmaceuticals's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

ASX:NEU vs VRTX, REGN, ALNY: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Neuren Pharmaceuticals's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuren Pharmaceuticals Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuren Pharmaceuticals's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Neuren Pharmaceuticals's Margin of Safety % (DCF FCF Based) falls into.


ASX:NEU
54GF Score
Neuren Pharmaceuticals Ltd ASX:NEU
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Neuren Pharmaceuticals (ASX:NEU) Overvalued in 2026?

Based on GuruFocus' analysis, Neuren Pharmaceuticals stock appears to be overvalued. The current stock price of A$12.76 is trading 109.9% above its estimated GF Value™ of A$6.08. GuruFocus considers Neuren Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ASX:NEU:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: A$6.08 vs. price of A$12.76 (109.9% above fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the ASX:NEU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuren Pharmaceuticals Business Description

Other Exchanges NURPF:USANK9:Germany
Address 117 Camberwell Road, Suite 1.01, Hawthorn East, Melbourne, VIC, AUS, 3123
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
54GF Score

Get the complete analysis for ASX:NEU

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$12.76
Price
A$6.08
GF Value